Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05996744 · ClinicalTrials.gov registry record · Phase 2
Study of Obeldesivir in Children and Adolescents With COVID-19
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05996744 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 3 participants.
The verdict
NCT05996744, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical study is to learn more about the safety and tolerability of obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19). The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and tolerability of ODV in pediatric participants with COVID-19.
Interventions
- DRUG Obeldesivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-12-26 |
| Est. Completion | 2024-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05996744
The ClinicalTrials.gov registry entry for NCT05996744 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Obeldesivir is the first listed.
NCT05996744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05996744 about?
NCT05996744 is a clinical study titled "Study of Obeldesivir in Children and Adolescents With COVID-19". The goal of this clinical study is to learn more about the safety and tolerability of obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19). The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and tolerability of ODV in pediatric particip...
What is the current status of trial NCT05996744?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2023-12-26. Estimated completion is 2024-02-23.
What interventions are being tested in trial NCT05996744?
The interventions under investigation include: Obeldesivir (DRUG).
Who is sponsoring clinical trial NCT05996744?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.